Enlituo versus Erbitux plus chemotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two antibody treatments (Enlituo and Erbitux, each combined with chemotherapy) for colorectal cancer that has spread locally or to other parts of the body. You may qualify if your cancer has a specific genetic profile (RAS/BRAF wild-type and MSS/pMMR status) and you have not yet received systemic chemotherapy for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Histologically or cytologically confirmed locally advanced or metastatic colorectal cancer
- Cancer must be RAS/BRAF wild-type and MSS/pMMR status (confirmed by local lab testing)
- No prior systemic anti-tumor therapy for advanced colorectal cancer (prior neoadjuvant or adjuvant therapy allowed if completed ≥6 months before recurrence)
- Adequate organ and bone marrow function (specific blood counts, liver, kidney, and heart function)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (able to carry out normal activities with little or no limitation)
- At least one measurable tumor lesion visible on imaging that has not been previously treated with local therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding cetuximab to standard chemotherapy can improve outcomes for people with colorectal cancer that has spread only to the liver. It aims to see if the combination works better when specific tumor markers (RAS/BRAF) are “wild type” and the liver disease can be removed.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
This study compares a new drug called HLX05-N with an approved drug called Erbitux (cetuximab) in people with advanced colorectal cancer that has spread. The trial tests whether the new drug works similarly or better than Erbitux.
This trial tests whether a combination of three drugs (cetuximabβ, envolimab, and mFOLFOX6) can help people with advanced colorectal cancer that has not been treated before. It is for people whose tumors have certain gene markers (RAS/BRAF wild-type and MSS).
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.